Document is current

Article History

Accepted: 21 November 2024

First Online: 23 January 2025

Declarations

:

: No external funding was used in the preparation of this manuscript.

: Elizabeth Catherine Smyth reported grants and personal fees from BMS and AstraZeneca; personal fees from Amgen, Daiichi-Sankyo, Merck, Viracta, Astellas, Novartis, Pfizer, Zymeworks, and BeiGene; personal fees and non-financial support from Mirati; support by the NIHR Biomedical Research Centre at Oxford. Elizabeth Catherine Smyth is an Editorial Board member of Drugs. Elizabeth Catherine Smyth was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Antonella Cammarota and Rachel Woodford declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.

: Ethics approval was not required for the formulation of this review.

: Not applicable.

: Consent for publication was not required for this review.

: All data used in this review are available online through the given references.

: No coding was used in the formulation of this review.

: All authors have contributed to the design, data collection and interpretation, drafting and critical review of the manuscript, and have approved its final version.